ESTpharm announced on the 27th that its Q2 2026 consolidated preliminary results showed a significant year-on-year increase in both revenue and operating profit.

[Q2 Performance Summary]

According to the disclosure, Q2 revenue stood at KRW 108.484 billion, up 58.9% from the same period last year (KRW 68.251 billion) and up 62.0% compared to the previous quarter (KRW 66.961 billion).

Operating profit reached KRW 18.307 billion, representing increases of 41.7% year-on-year (KRW 12.919 billion) and 58.8% quarter-on-quarter (KRW 11.529 billion), respectively.

Profit before income tax from continuing operations amounted to KRW 18.136 billion, surging 162.4% year-on-year and increasing 2.6% from the previous quarter.

Net income was KRW 13.151 billion, soaring 145.0% year-on-year, but decreasing 13.5% quarter-on-quarter. Net income attributable to owners of the parent company was KRW 13.210 billion, jumping 143.5% year-on-year, though declining 12.3% from the previous quarter.

[H1 Cumulative Performance]

On a cumulative basis for the first half (January–June), the company recorded revenue of KRW 175.445 billion and operating profit of KRW 29.836 billion. Compared to the same period last year, revenue grew 45.4% and operating profit surged 114.0%.

During the same period, profit before income tax from continuing operations was KRW 35.803 billion (up 322.7% YoY), net income was KRW 28.352 billion (up 366.6% YoY), and net income attributable to owners of the parent company was KRW 28.273 billion (up 337.1% YoY).

[Notes]

The company explained that these results are consolidated preliminary figures prepared in accordance with the Korean International Financial Reporting Standards (K-IFRS) and have not been reviewed or audited by an external auditor, meaning they may differ from the finalized results.